Grigoris Gerotziafas on VTE in MM and BCMA: We Are Pleased to Announce Our New Systematic Review
Grigoris Gerotziafas, Director of the Cancer, Vessels, Biology, and Therapeutics (CaVITE) Research Department, Head of the CRSA at Sorbonne University, shared on LinkedIn
about a recent article he and his colleagues co-authored, adding:
”Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy: A systematic review.
We are pleased to announce our new systematic review leaded by Dr Pedro Las Casas, Associated Researcher in CaVITE Team – Thrombosis Center (G Gerotziafas), CRSA Sorbonne Univeristy:
This work was conducted by the CaVITE team (CRSA, INSERM, Sorbonne University), in collaboration with expert groups from:
- Hematology Department, University Hospital Morales Meseguer and IMIB/CIBERER, Murcia, Spain
- Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- Loyola University Stritch School of Medicine, Maywood (IL), USA
- Hospital Papa Giovanni XXIII, Bergamo, Italy
- Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, Sechenov University, Moscow, Russia
Key message: The reported incidence of venous thromboembolism (VTE) after BCMA-directed CAR T-cell therapy in multiple myeloma is low, but likely underestimated, particularly in real-world studies.
When thrombotic events are actively sought and systematically documented, VTE rates appear comparable to those expected in relapsed/refractory multiple myeloma patients receiving standard thromboprophylaxis.
These findings emphasize the need for stronger methodological rigor in assessing and reporting thrombotic complications in CAR T-cell therapy, rather than supporting definitive conclusions regarding thrombotic safety or prophylaxis adequacy.
Reference:
Las Casas PHFDC, Marco-Ayala J, Lefkou EE, Soares TS, Baghdadi MA, Kempaiah P, Fareed J, Vandreden P, Hungria V, Marchetti M, Falanga A, Garderet L, Gerotziafas G. Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review. Br J Haematol. 2026 Feb 1. doi: 10.1111/bjh.70356. Epub ahead of print. PMID: 41622574.”
Title: Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review
Authors: Pedro Henrique Fernandes do Carmo Las Casas, Javier Marco-Ayala, Elmina-Eleftheria Lefkou, Thamiris Silva Soares, Mohammed A. Baghdadi, Prakasha Kempaiah, Jawed Fareed, Patrick Vandreden, Vania Hungria, Marina Marchetti, Anna Falanga, Laurent Garderet, Grigoris Gerotziafas
Read the Full Article on BJHaem
Stay updated on all scientific advances with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers